Inflammation Review: FDA Approves New Dupixent Dose, Probiotic Mixture Proves Effective for AD, and More

Highlighting the latest inflammation-related news reported across MJH Life Sciences™.

In recent inflammation news, the FDA approved a new dose for dupilumab prefilled pens, a probiotic mixture was effective at treating atopic dermatitis (AD), and adding platelet-rich plasma (PRP) to phototherapy improved AD severity scores.

FDA Approves New Dupilumab Dose

A 200-mg single-dose prefilled pen of dupilumab (Dupixent) will soon be available to patients with AD and asthma, after receiving approval from the FDA, according to a report from Dermatology Times®.

The prefilled pen allows for at-home administration for patients 12 years and older. The approval comes shortly after the 300-mg prefilled pen was approved and the developers, Sanofi and Regeneron, launched it on the US market.

Learn more about the approval in Dermatology Times®.

Study Suggests Probiotic Mixture Is an Effective AD Therapy

Study results showed that oral administration of probiotic mixtures was effective at reducing AD severity in children. The mixtures also proved effective at restoring gut microbiota and decreasing inflammation in the intestines.

According to a report from HCP Live®, an open clinical trial performed on 25 children aged 3 to 10 years with AD demonstrated reduced fecal calprotectin levels after 4 weeks of administration of the mixture, which also led to diminished intestinal inflammation.

Learn more about the study in HCP Live®.

Adding PRP to Phototherapy Improves AD Severity

Adding platelet-rich plasma (PRP) injections to narrowband-ultraviolet B (NB-UVB) phototherapy may be an effective and efficient mode for treating AD, as reported by HCP Live®. Investigators in Egypt said that the intradermal injection was able to reduce the therapeutic period needed for NB-UVB therapy.

Among the 44 patients included in the study, the group that received NB-UVB in conjunction with PRP overall saw a greater reduction in Eczema Area and Severity Index (EASI) scores (from 46.4 to 2.4) compared with the group that only received NB-UVB (44.4 to 6.2). At week 12, 74.46% of patients treated with NB-UVB and PRP achieved EASI reduction compared with 65.23% of patients only treated with NB-UVB.

Learn more about the study in HCP Live®.